AerWave Medical, Inc. is advancing an interventional approach designed to treat severe asthma, chronic obstructive pulmonary disease (COPD), and other advanced lung diseases. The company is targeting significant U.S. addressable markets that include roughly 4 million COPD patients and 2.5 million asthma patients. Management emphasizes that AerWave holds broad intellectual property protection around its technology, which it believes creates defensible competitive advantages. Led by CEO Jeff O’Donnell, the executive team has prior experience in building and exiting medical-device ventures. Proceeds from its recent financing will be directed toward continued development of the AerWave technology and preparation for broader clinical use worldwide. While revenue and user metrics have not been disclosed, the company’s focus remains on product development and clinical validation.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2021